MedTrace Logo

To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

NCT06409650 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2024-05-22

No results posted yet for this study

Summary

This was a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study of KX-826 Tincture in Chinese adult female subjects with AGA.

Conditions

Interventions

DRUG

KX-826 dosed at 2.5mg

2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks

DRUG

KX-826 dosed at 2.5mg

2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

DRUG

KX-826 dosed at 5 mg

5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks

DRUG

KX-826 dosed at 5 mg

5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

DRUG

Matching placebo to KX-826

Placebo applied topically to scalp once daily for 24 weeks

DRUG

Matching placebo to KX-826

Placebo applied topically to scalp twice daily for 24 weeks

Sponsors & Collaborators

  • Suzhou Koshine Biomedica, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-09
Primary Completion
2022-11-10
Completion
2023-12-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06409650 on ClinicalTrials.gov